ABSTRACT
Pulmonary involvement is frequent in systemic sclerosis, which leads to reduction in lung volumes and gas transfer across the alveolocapillary barrier and alteration of the pulmonary functions. The aim of this work was to study the pulmonary [functional and structural] changes in patients with systemic sclerosis. Thirty subjects comprised the material of this study, twenty of them had systemic sclerosis and ten were normal healthy volunteers as a control group. They were subjected to thorough history taking, complete clinical examination, PFT, BAL, CXR, 2D Echocardiography and HRCT. It was found that the mean values of FVC and DLCO were significantly lower in sysiemic sclerosis patients than those in normal control group. Also the lymphocytes, granulocytes, IgG and albumin in BAL fluid of patients with systemic scterosis were significantly higher than that in the normal control. HRCT scores were significantly higher in systemic sclerosis patients than normal control and also were higher in patients with abnormal BAL than those with normal BAL. It was concluded that: 1. Patients with systemic sclerosis have an inflammatory aiveolitis with hypercellularity and increased percentage of granulocytes recovered from the lower respiratory tract by BAL. 2. The significant correlalion between the degree of alveolitis and the degree of decline in PFT in such patients, increases the value oi BAL in identification of high risk group. 3. HRCT is an excellent radiodiagnostic tool for quantification of lurig lesions in systemic sclerosis and also for predication of sequale of these lesions on pulmonary functions
Subject(s)
Humans , Male , Female , Signs and Symptoms, Respiratory , Respiratory Function Tests , Bronchoalveolar Lavage/analysis , Radiography, Thoracic , Tomography, X-Ray Computed , EchocardiographyABSTRACT
The aim of this study was to measure senun levels of matrix metalloproteinases-2and -9 [MMP-2 and -9] and tissue inhibitor of matrix metalloproteinase-1 [TIMP-1] in non-small cell lung cancer [NSCLC] patients and to detect any potential role of these parameters in tumour growth, invasion and metastasis. The present study entailed 49 patients with primary NSCLC and 10 healthy non-smoker volunteers as a control group. All lung cancer patients were subjected to CT imaging and fiberoptic bronchoscopy with biopsy taking for histological diagnosis. Transthoracic fine needle aspiration lung biopsy or open lung biopsy was performed in patients with negative fiberoptic bronchoscopic results. Serum levels of MMP-2, MMP-9, and TIMP-1 were measured in both NSCLC patients and the controls by one-step sandwich enzyme immunoassay specific for each parameter. The current study revealed significant increase in the mean serum levels of MMP-2, MMP-9, and TIMP-1 in NSCLC patients than in the control group [P<0.0001]. It also revealed that 61.22%, 48.99%, and 53.06% of NSCLC patients had respectively serum MMP-2, MMP-9, and TIMP-1 levels higher than the corresponding cutoff values of the mean +2SD in the healthy controls. The study also showed significant positive association between the serum levels of these parameters and the TNM stage of the disease [P = 0.01, 0.03, and 0.01 for MMP-2, MMP-9, and TIMP-1 respectively]. The study also revealed significant differences in serum levels of such parameters in adenocarcinoma [AdC] versus squamous cell carcinoma [SqCC] [P = 0.03 for both MMP-2 and TIMP-1 and 0.02 for MMP-9]. Serum levels of MMP-2, MMP-9, and TIMP-1 are elevated in NSCLC patients and are associated with the TNM stage of the disease suggesting important roles of such parameters in growth, invasion, and metastasis of NSCLC. The elevated levels of such parameters in AdC than in SqCC may relate to the greater tendency of the former for systemic metastasis. This study suggests that serum MMP-2, MMP-9, and TIMP-1 may be used as useful markers of NSCLC invasion and metastasis